- •
Instill BCG after a minimum of 2 wk following a TURBT.
- •
Teach proper catheterisation techniques to administering health care professionals.
- •
Defer BCG instillations for 1 wk if catheterisation is traumatic.
- •
If gross hematuria is present, delay BCG until this has resolved.
- •
If the patient has a UTI, then defer BCG for 1 wk until resolution of the UTI with
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events☆
Introduction
Intravesical therapy is an integral part of the management of non-muscle invasive bladder cancer (NMIBC). Both intravesical chemotherapy and bacillus Calmette-Guérin (BCG) have potential side effects which can be described as local or systemic. Local side effects are common for both therapies and can lead to treatment cessation and incomplete treatment, resulting in suboptimal outcomes. BCG-related adverse events can be treated successfully in most patients, even those patients with serious side effects [1]. The keys to management of these adverse events are education, prevention, and awareness. Furthermore, it should be noted that BCG-associated side effects are generally seen during induction and during the first 6 mo of maintenance BCG [1], [2]. During further maintenance, BCG-related adverse events do not significantly increase, and instillations are generally well tolerated [1].
This article summarizes the local and systemic side effects associated with intravesical therapy and presents the International Bladder Cancer Group's (IBCG) recommendations for the effective management of these adverse events based on currently available evidence. Strategies for the prevention of BCG-related adverse events, such as education, dose reductions, and the use of ofloxacin are also reviewed.
Section snippets
Local side effects common to both intravesical chemotherapy and bacillus Calmette-Guérin
Cystitis and hematuria are the most common local side effects of intravesical therapy, but they usually resolve 48 h after instillation. More severe, but less common, are local adverse events that include contracted bladder and ureteral obstruction.
Local side effects specifically associated with bacillus Calmette-Guérin
More severe local side effects associated with BCG therapy include granulomatous prostatitis and epididymo-orchitis.
Contact dermatitis
Contact dermatitis has been reported in up to 19% of patients treated with intravesical mitomycin C [4] and often leads to eczema-like desquamation of the skin on the palms, soles, perineum, chest, and face [17]. A case of penile gangrene resulting from contact dermatitis following intravesical administration of mitomycin C has recently been reported. The gangrene required penectomy 3 mo after the instillation [18].
Careful cleansing of the hands after drug-handling and cleansing of the genitals
Systemic side effects associated with bacillus Calmette-Guérin
Systemic side effects are less frequent than local side effects but are more likely to be severe. The most common systemic side effects associated with BCG therapy are general malaise, fever, myalgia, and nausea. Low-grade fever has been shown to develop in about 30.5% of BCG-treated patients, while fever greater than 39 °C has been reported in 5–20%. These side effects generally resolve within 48 h with or without the use of antipyretics as symptomatic treatment; however, persistent high-grade
Myelosuppression
Although rare, myelosuppression has been noted in patients treated with mitomycin C [22], [23] and may result from the use of high-concentration instillations into a bladder that has recently been traumatized [4].
The management of myelosuppression involves cessation of intravesical chemotherapy and monitoring of white blood cell (WBC) count.
The International Bladder Cancer Group's recommendations for the management of intravesical therapy–associated adverse events
The IBCG's recommendations for the management of intravesical therapy–associated adverse events are summarized in Table 1. This table also includes the following World Health Organization grading of toxic drug effects, which can be used as a guide for determining when intravesical therapy may be contraindicated [7]:
- •
Grade 1: Moderate and <48 h (usually require no modification of intravesical therapy)
- •
Grade 2: Severe and/or >48 h (usually require suspension of instillations until resolution of
Strategies for the prevention of bacillus Calmette-Guérin–associated adverse events
Strategies that may help prevent BCG-associated adverse events include education, dose reductions, and the use of ofloxacin. Other strategies that have been proposed but not reviewed in this section include concomitant use of isoniazid, decreasing the dwell time of BCG, and the addition of other immune-modulators.
The International Bladder Cancer Group's recommendations for the prevention of bacillus Calmette-Guérin–associated adverse events
Based on the review of potential strategies for the prevention of BCG-associated adverse events, the IBCG has proposed the following recommendations:
References (28)
- et al.
Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial
Eur Urol
(2003) - et al.
Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer
Urology
(2001) - et al.
The quality of life during intravesical bacillus Calmette-Guérin therapy
J Urol
(1996) - et al.
Complications of intravesical chemotherapy
Urol Clin North Am
(1992) - et al.
Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial
J Urol
(2001) - et al.
Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of cancer protocol 30911
J Urol
(1997) - et al.
A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma
J Urol
(1996) - et al.
Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures
Urology
(2005) Complications of bacillus Calmette-Guérin immunotherapy
Urol Clin North Am
(1992)- et al.
Transrectal ultrasound appearance of prostatic granulomas secondary to bacillus Calmette-Guérin instillation
J Urol
(1997)
Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma
Urology
A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin. Participating clinics
J Urol
Interference of modern antibacterials with bacillus Calmette-Guerin viability
J Urol
Complications of intravesical therapy for urothelial cancer of the bladder
J Urol
Cited by (97)
BCG mycotic aneurysm: Case report on a rare entity
2023, Urology Case ReportsVascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature
2023, Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesSupportive Care Needs of Patients on Surveillance and Treatment for Non-Muscle-Invasive Bladder Cancer
2021, Seminars in Oncology NursingLow compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review
2020, Urologic Oncology: Seminars and Original InvestigationsIntravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
2020, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.